Effects of bazedoxifene on bone mineral density, bone turnover, and safety in postmenopausal japanese women with osteoporosis

Journal of Bone and Mineral Research

Volumn 26, Issue 3, 2011, Pages 519-529

  Itabashi, Akira ^a   Yoh, Kousei ^b   Chines, Arkadi A ^c   Miki, Takami ^d   Takada, Masahiko ^e   Sato, Hiroshi ^f   Gorai, Itsuo ^g,h   Sugimoto, Toshitsugu ⁱ   Mizunuma, Hideki ^j   Ochi, Hiroshi ^c   Constantine, Ginger D ^c   Ohta, Hiroaki ^f  

^a Saitama Livestock Research Center   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c PFIZER INC   (United States)

^d OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^f TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^g International University of Health and Welfare   (Japan)

^h Hori Hospital   (Japan)

ⁱ SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^j HIROSAKI UNIVERSITY   (Japan)

more..

Author keywords

Bazedoxifene; bone mineral density; postmenopausal osteoporosis; serms; treatments

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BAZEDOXIFENE; BIOLOGICAL MARKER; CALCIUM DERIVATIVE; CALCIUM PLUS MAGNESIUM PLUS VITAMIN D3; CARBOXY TERMINAL TELOPEPTIDE; COLECALCIFEROL DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAGNESIUM DERIVATIVE; OSTEOCALCIN; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ANGINA PECTORIS; ARTHRALGIA; ARTICLE; BACKACHE; BONE DENSITY; BONE TURNOVER; BRAIN INFARCTION; BREAST CANCER; BREAST CYST; BREAST TUMOR; CAROTID ARTERY THROMBOSIS; CONSTIPATION; CONTACT DERMATITIS; CONTUSION; COUGHING; CYSTITIS; DENTAL CARIES; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECZEMA; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; FEMALE; FEMUR NECK; FIBROCYSTIC BREAST DISEASE; GASTRITIS; GENITAL BLEEDING; GINGIVITIS; GREATER TROCHANTER; HEADACHE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HIP; HOT FLUSH; HUMAN; HYPESTHESIA; INCIDENCE; INSOMNIA; JAPANESE; LIMB PAIN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MASTALGIA; MORNING DOSAGE; MULTICENTER STUDY; MUSCLE SPASM; MUSCULOSKELETAL STIFFNESS; OVARY CYST; PERIARTHRITIS; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; STOMACH DISCOMFORT; STOMATITIS; TREATMENT DURATION; TREATMENT RESPONSE; UTERINE CERVIX CANCER; VAGINA DISCHARGE; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE; VOMITING;

ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; DEMOGRAPHY; FEMALE; HUMANS; INCIDENCE; INDOLES; JAPAN; LIPID METABOLISM; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES;

EID: 79951848520     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.252     Document Type: Article

References (23)

1. North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of the North American Menopause Society. Menopause. 2006; 13: 340-367.
2. Caliri A, De Filippis L, Bagnato GL, Bagnato GF,. Osteoporotic fractures: mortality and quality of life. Panminerva Med. 2007; 49: 21-27.
3. Papaioannou A, Kennedy CC, Dolovich L, Lau E, Adachi JD,. Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging. 2007; 24: 37-55. (Pubitemid 46148080)
4. Nakamura T, Liu JL, Morii H, et al. Effect of raloxifene on clinical fractures in Asian women with postmenopausal osteoporosis. J Bone Miner Metab. 2006; 24: 414-418. (Pubitemid 44306179)
5. Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-year results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res. 2008; 23: 525-535. (Pubitemid 351501893)
6. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res. 2008; 23: 1923-1934.
7. Orimo H, Hayashi Y, Fukunaga M, et al. Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab. 2001; 19: 331-337. (Pubitemid 33041725)
8. Black DM, Palermo L, Nevitt MC, Genant HK, Christensen L, Cummings SR, for the Study of Osteoporotic Fractures Research Group. Defining incident vertebral deformity: a prospective comparison of several approaches. J Bone Miner Res. 1999; 14: 90-101. (Pubitemid 29021608)
9. Genant HK, Wu CY, van KC, Nevitt MC,. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993; 8: 1137-1148. (Pubitemid 23261108)
10. Genant HK, Jergas M, Palermo L, et al. for the Study of Osteoporotic Fractures Research Group. Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. J Bone Miner Res. 1996; 11: 984-996. (Pubitemid 26200050)
11. Morii H, Ohashi Y, Taketani Y, et al. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial. Osteoporos Int. 2003; 14: 793-800. (Pubitemid 37462128)
12. Kanis JA, Johansson H, Oden A, McCloskey EV,. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone. 2009; 44: 1049-1054.
13. McCloskey E, Johansson H, Oden A, Chines A, Kanis J,. Assessment of the effect of bazedoxifene on non-vertebral fracture risk. J Bone Miner Res. 2009; 24 (Suppl 1): Available at:. Accessed December 10, 2009.
14. Arun B, Anthony M, Dunn B,. The search for the ideal SERM. Expert Opin Pharmacother. 2002; 3: 681-691. (Pubitemid 34649697)
15. Davies GC, Huster WJ, Lu Y, Plouffe L Jr, Lakshmanan M,. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol. 1999; 93: 558-565. (Pubitemid 29147076)
16. Ettinger B, Black DM, Mitlak BH, et al. for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999; 282: 637-645. (Pubitemid 29384151)
17. Grady D, Ettinger B, Moscarelli E, et al. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet Gynecol. 2004; 104: 837-844. (Pubitemid 40458815)
18. Chim H, Tan BH, Ang CC, Chew EM, Chong YS, Saw SM,. The prevalence of menopausal symptoms in a community in Singapore. Maturitas. 2002; 41: 275-282. (Pubitemid 34603396)
19. Melby MK, Lock M, Kaufert P,. Culture and symptom reporting at menopause. Hum Reprod Update. 2005; 11: 495-512. (Pubitemid 41418804)
20. Rice VM,. Strategies and issues for managing menopause-related symptoms in diverse populations: ethnic and racial diversity. Am J Med. 2005; 118 (Suppl): 142-147.
21. Shea JL,. Chinese women's symptoms: relation to menopause, age and related attitudes. Climacteric. 2006; 9: 30-39. (Pubitemid 43155681)
22. Pinkerton JV, Archer DF, Utian WH, et al. Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis. Menopause. 2009; 16: 1102-1108.
23. Archer DF, Pinkerton JV, Utian WH, et al. Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause. 2009; 16: 1109-1115.